Board & Management
An experienced team of scientists, clinicians, and operators
Board of Directors
Executive Chairman
Dr Stergiopoulos is a physician executive with significant experience in the Pharmaceutical/Biotech industry, especially in Oncology. He is the former Chief Medical Officer of multi-billion dollar Euronext listed Ipsen and has held appointments as an Attending Physician and trainee in institutions such as Albert Einstein College of Medicine, Harvard Medical School and the National Institutes of Health. He holds a Masters in Biotechnology Enterprise and Entrepreneurship (MBEE) from The Johns Hopkins University and a Medical Degree from Poznan University of Medical Sciences (Poland). Sotirios is a Fellow of the American College of Physicians, the New York Academy of Medicine as well as the Royal Society of Medicine (UK). He is also a Member of the American Association for Cancer Research and of the American Society of Clinical Oncology. In October 2017 Dr Stergiopoulos was appointed President of the Board of Governors for the Accreditation Council for Medical Affairs.
Chief Executive Officer
Mr Vempati brings nearly two decades of extensive expertise in drug discovery, oncology research, and business strategy with a track record of advancing novel therapeutics from concept to clinical development. Prior to founding Coiled Therapeutics, Inc, he co-founded A2A Pharmaceuticals, Inc in 2016, where he serves as Chief Strategy Officer and Executive Vice President of Research Development, overseeing computational drug design platforms and pipeline advancement. Earlier in his career he held forecasting and business development roles at Ironwood Pharmaceuticals and Rafael Pharmaceuticals and served as an Equity Research analyst at Jefferies LLC analysing biotechnology investments. He has completed a postdoctoral fellowship in leukaemia research at Dana Farber Cancer Institute (Harvard University). He holds a PhD in molecular biology from Ludwig-Maximilians-University, Germany, an MBA from Boston University, and an MS degree from Guru Nanak Dev University, India.
Non-Executive Director
Dr Dean brings extensive leadership experience across clinical, academic and corporate settings. He currently consults for GenesisCare, a global provider of integrated cancer care, and serves as Head of Oncology at St John of God Subiaco Hospital in Western Australia, home to one of the region's busiest private hospital clinical trials units. He oversees a range of studies in pancreatic, gastrointestinal and gynaecological cancers. Under his leadership, the hospital received the Outstanding Site Award from the Australasian GastroIntestinal Trials Group. In addition to his clinical roles, Dr Dean is a board member of Valo Therapeutics, a clinical-stage immunotherapy company developing novel treatments for cancer and infectious diseases. He is also the founder of the award-winning health information platform, virtualmedicalcentre.com.
Non-Executive Director
Ms Duvall is highly accomplished in the biotech and pharma sector, with over 25 years of experience in executive roles in the industry. During this time, Ms Duvall acted for Ferring Pharmaceuticals, as one of the executive board members who built the company from a US$700 million to US$2 billion in revenue. Jean has a significant track record in corporate development, having led multiple successful M&A, divestment and licensing deals throughout her career. She previously had the role of General Counsel at Elan Corporation and was legal lead, negotiating the divestment of over $2 billion in assets. Additionally, she has co-founded and led biopharma start-ups including Trizell and Amzell, resulting in multiple products having successful Phase II and Phase III clinical studies. Ms Duvall is currently CEO and co-founder of ReproNovo SA and a non-executive director of Ondine Biomedical Inc. (AIM:OBI).
Non-Executive Director
Craig Tooman has more than 30 years of international pharmaceutical and biotechnology leadership experience, including over 20 years as a public company CEO and CFO. He has directly participated in raising nearly US$9 billion in capital. Most recently he was President, CEO and Board Director of Silence Therapeutics. There he helped transform the business from an early-stage UK research company trading on AIM into a NASDAQ-listed global siRNA company with multiple assets in later-stage trials. In October 2026, Silence Therapeutics agreed to be acquired by Merck KGaA for approximately US$1.3 billion. As CEO of Aratana Therapeutics, he negotiated its US$250 million merger with Elanco. At ILEX Oncology, he led its US$1.1 billion acquisition by Genzyme. He served on the Supervisory Board of CureVac until BioNTech acquired it in 2025, and he has chaired the Audit Committees of four boards. His oncology track record, which earned him CPRIT’s first Entrepreneur in Residence designation, fits closely with Coiled Therapeutics’ precision oncology focus and lead candidate, AO-252.
Non-Executive Director
Mr West is an experienced Fellow Chartered Accountant (CA ANZ) and ACA (ICAEW), with over 30 years' financial and corporate experience gained in public practice, life sciences, oil and gas, mining and investment banking. Mr West has held several senior positions in public companies, including PetroNor E&P Limited, where he was Executive Director and Chief Financial Officer and instrumental in the successful US$100 million merger of African Petroleum Corporation Ltd and PetroNor E&P Limited in August 2019. Mr West was also a Non-Executive Director of ASX-listed Apollo Consolidated Limited, a company acquired for A$181 million in 2021. He is also co-founder and non-executive director of TollCyto Therapeutics Ltd.